NCT06854653 2026-02-03
A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCL
Prescient Therapeutics, Ltd.
Phase 2 Recruiting
Prescient Therapeutics, Ltd.
Memorial Sloan Kettering Cancer Center
City of Hope Medical Center
Stanford University